Abstract
Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluatedin vitro andin vivo. Although CD3+CD56+ cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarnas, J. C., Linn, Y. C., Hope, E. G., and Negrin, R. S., Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.Biol. Blood Marrow Transplant., 7,216–222 (2001).
Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., and Negrin, R. S., Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.Stood, 97, 2923–2931 (2001).
Barber, A., Zhang, T., DeMars, L. R., Conejo-Garcia, J., Roby, K. F., and Sentman, C. L., Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.Cancer Res., 67, 5003–5008 (2007).
Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., Gall, J. M., Schulz, S., Thome, S. H., Teng, N. N., Contag, C. H., Lum, L. G., and Negrin, R. S., Enhanced killing of primary ovarian cancer by retargeting autologous cytokine- induced killer cells with bispecific antibodies: a preclinical study.Clin. Cancer Res., 12,1859–1867 (2006).
Chung, H. H., Hwang, S. Y., Jung, K. W., Won, Y. J., Shin, H. R., Kim, J. W., and Lee, H. P., Ovarian cancer incidence and survival in Korea: 1993-2002.Int. J. Gynecol. Cancer, 17, 595–600 (2007).
Grabert, R. C., Cousens, L. P., Smith, J. A., Olson, S., Gall, J., Young, W. B., Davol, P. A., and Lum, L. G., Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.Clin. Cancer Res., 12, 569–576 (2006).
Han, S. B., Lee, C. W., Jeon, Y. J., Hong, N. D., Yoo, I. D., Yang, K. H., and Kim, H. M., The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis.Immunopharmacology, 41,157–164 (1999).
Han, S. B., Lee, C. W., Yoon, Y. D., Kang, J. S., Lee, K. H., Yoon, W. K., Kim, Y. K., Lee, K., Park, S. K., and Kim, H. M., Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A.Biochem. Pharmacol., 70, 1518–1526 (2005a).
Han, S. B., Moratz, C., Huang, N. N., Kelsall, B., Cho, H., Shi, C. S., Schwartz, O., and Kehrl, J. H., Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles.Immunity, 22, 343–354 (2005b).
Kalinski, P., Nakamura, Y., Watchmaker, P., Giermasz, A., Muthuswamy, R., and Mailliard, R. B., Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines.Immunol. Res., 36, 137–146(2006).
Karimi, M., Cao, T. M., Baker, J. A., Verneris, M. R., Soares, L. and Negrin, R. S., Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.J. Immunol., 175, 7819–7828 (2005).
Kim, J. Y., Yoon Y. D., Ahn, J. M., Kang, J. S., Park, S. K., Lee, K., Song, K. B., Kim, H. M., and Han, S. B., Angelan isolated from Angelica gigas Nakai induces dendritic cell maturation through toll-like receptor 4.Int Immunopharmacol., 7, 78–87 (2007).
Kornacker, M., Moldenhauer, G, Herbst, M., Weilguni, E., Tita-Nwa, F., Harter, C., Hensel, M., and Ho, A. D., Cytokine- induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.Int. J. Cancer, 119,1377–1382 (2006).
Law, K. S., Chen, H. C., and Liao, S. K., Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine- activated killer cells.Anticancer Res., 27, 841–850 (2007).
Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., and Negrin, R. S., A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non- Hodgkin lymphoma.Biol. Blood Marrow Transplant, 11,181–187(2005).
Lu, P. H. and Negrin, R. S., A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.J. Immunol., 153,1687–1696 (1994).
Raja Gabaglia, C., Diaz de Durana, Y., Graham, F. L., Gauldie, J., Sercarz, E. E., and Braciak, T. A., Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class l-negative LNCaP prostate tumors.Cancer Res., 67, 2290–2297 (2007).
Schmidt-Wolf, I. G, Negrin, R. S., Kiem, H. P., Blume, K. G, and Weissman, I. L., Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.J. Exp. Med, 174,139–149 (1991).
Suh, S. I., Pyun, H. Y., Cho, J. W., Baek, W. K., Park, J. B., Kwon, T., Park, J. W., Suh, M. H., and Carson, D. A., 5-Aza-2′- deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines.Cancer Lett., 160, 81–88 (2000).
Sun, S., Li, X. M., Li, X. D., and Yang, W. S., Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines.Cancer Biother. Radiopharm., 20,173–180(2005).
Takashima, K., Fujiwara, H., Inada, S., Atsuji, K., Araki, Y., Kubota, T., and Yamagishi, H., Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.Anticancer Res., 26, 3327–3332 (2006).
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet, 356, 802–807 (2000).
Thorne, S. H., Hermiston, T., and Kirn, D., Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.Semin. Oncol., 32, 537–548 (2005).
Thorne, S. H. and Kirn, D. H., Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.Expert Opin. Biol. Then, 4, 1307–1321 (2004).
Thorne, S. H., Negrin, R. S., and Contag, C. H., Synergistic antitumor effects of immune cell-viral biotherapy.Science, 311,1780–1784(2006).
Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y. A., Marina, N., Contag, C. H., and Negrin, R. S., Low levels of Her2/neu expressed by Ewing’s family tumor cell lines can redirect cytokine-induced killer cells.Clin. Cancer Res., 11,4561–4570 (2005).
Wang, H., Zhou, F. J., Wang, Q. J., Qin, Z. K., Huang, L.X., Liu, Z. W., Han, H., Li, Y. Q., Chen, S. P., and Xia, J. C., Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma—a report of ten cases.Ai Zheng, 25,625–630 (2006a).
Wang, W., Epler, J., Salazar, L. G, and Riddell, S. R., Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.Cancer Res., 66, 6826–6833 (2006b).
Yang, X. J., Huang, J. A., Lei, W., Zhu, Y. B., and Zhang, X. G., Antitumor effects of cocultured dendritic cells and cytokine- induced killer cells on lung cancer in vitro and in vivo.Ai Zheng, 25,1329–1333 (2006).
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., and Coukos, G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N. Engl. J. Med., 348, 203–213 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, H.M., Kang, J.S., Lim, J. et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30, 1464–1470 (2007). https://doi.org/10.1007/BF02977372
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977372